About TScan Therapeutics, Inc.
https://www.tscan.comTScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer.
CEO
Gavin MacBeath
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 2 of 13
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
LYNX1 CAPITAL MANAGEMENT LP
Shares:7.86M
Value:$9.43M
BVF INC/IL
Shares:5.23M
Value:$6.27M
BLACKROCK INC.
Shares:4.46M
Value:$5.35M
Summary
Showing Top 3 of 80
About TScan Therapeutics, Inc.
https://www.tscan.comTScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $2.51M ▼ | $38.8M ▼ | $-35.71M ▲ | -1.42K% ▼ | $-0.28 | $-34.24M ▲ |
| Q2-2025 | $3.08M ▲ | $41.73M ▲ | $-36.95M ▼ | -1.2K% ▲ | $-0.28 ▼ | $-35.56M ▼ |
| Q1-2025 | $2.17M ▲ | $38.42M ▲ | $-34.13M ▲ | -1.57K% ▲ | $-0.26 ▲ | $-32.77M ▲ |
| Q4-2024 | $665K ▼ | $37.38M ▲ | $-35.81M ▼ | -5.38K% ▼ | $-0.3 ▼ | $-34.31M ▼ |
| Q3-2024 | $1.05M | $33.67M | $-29.89M | -2.85K% | $-0.25 | $-27.9M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $184.45M ▼ | $262.23M ▼ | $118.2M ▼ | $144.02M ▼ |
| Q2-2025 | $218.04M ▼ | $298.56M ▼ | $121.85M ▼ | $176.71M ▼ |
| Q1-2025 | $251.69M ▼ | $332.71M ▼ | $122.51M ▼ | $210.2M ▼ |
| Q4-2024 | $290.11M ▲ | $371.12M ▲ | $130.15M ▲ | $240.97M ▲ |
| Q3-2024 | $271.12M | $348.03M | $118.94M | $229.09M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-35.71M ▲ | $-32.46M ▲ | $32.58M ▼ | $0 ▼ | $112K ▼ | $-33.89M ▲ |
| Q2-2025 | $-36.95M ▼ | $-33.27M ▲ | $48.44M ▲ | $116K ▲ | $15.29M ▲ | $-34.55M ▲ |
| Q1-2025 | $-34.13M ▲ | $-37.59M ▼ | $13.53M ▼ | $-525K ▼ | $-24.58M ▼ | $-39.12M ▼ |
| Q4-2024 | $-35.81M ▼ | $-27.41M ▲ | $27.29M ▲ | $45.69M ▲ | $45.57M ▲ | $-28.3M ▲ |
| Q3-2024 | $-29.89M | $-27.92M | $-82.35M | $1.23M | $-109.04M | $-29.29M |
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|
 Reportable Segment | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Gavin MacBeath
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 2 of 13
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
LYNX1 CAPITAL MANAGEMENT LP
Shares:7.86M
Value:$9.43M
BVF INC/IL
Shares:5.23M
Value:$6.27M
BLACKROCK INC.
Shares:4.46M
Value:$5.35M
Summary
Showing Top 3 of 80